Spironolactone Increases Nitric Oxide Bioactivity, Improves Endothelial Vasodilator Dysfunction, and Suppresses Vascular Angiotensin I/Angiotensin II Conversion in Patients With Chronic Heart Failure
Top Cited Papers
- 15 February 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 101 (6), 594-597
- https://doi.org/10.1161/01.cir.101.6.594
Abstract
Background—The RALES study showed that spironolactone, added to conventional therapy for chronic heart failure, dramatically reduced mortality. We tested the hypothesis that this benefit was partia...Keywords
This publication has 7 references indexed in Scilit:
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?British Journal of Clinical Pharmacology, 1999
- Nitric Oxide Regulates Renin Release During Salt Depletion but Does Not Alter Angiotensin Responses in Normal HumansJournal of Cardiovascular Pharmacology and Therapeutics, 1999
- K+ is an endothelium-derived hyperpolarizing factor in rat arteriesNature, 1998
- Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients.Published by Oxford University Press (OUP) ,1998
- Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 βEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses.Hypertension, 1992